Last reviewed · How we verify

NCT04139954: BioSTaR

Observational Registry of Patients With Rheumatoid Arthritis /Spondyloarthritis Using Biological or Targeted Synthetic DMARDs

Status unknown Last updated 29 October 2019
What this trial tests

trial testing There is no intervention in the study in Rheumatoid Arthritis in 1,400 participants. Status unknown.

Timeline
1 February 2019
Primary endpoint
1 March 2020
1 March 2024

Quick facts

Lead sponsorTurkish League Against Rheumatism
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,400
Start date1 February 2019
Primary completion1 March 2020
Estimated completion1 March 2024
Sites14 locations across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Turkish League Against Rheumatism

Who can join

18 and older, any sex, with Rheumatoid Arthritis or Spondyloarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, investigators aimed to observe the examination findings, laboratory findings and drugs used in routine polyclinic controls of the participants using biological and targeted synthetic disease-modifying antirheumatic drug (DMARD) and the doses and side effects of these drugs. The aim of this registry is to evaluate the real-life data of participants receiving these medications. Analysis of treatment follow-up, drug changes, causes of change, treatment-related paradoxic / immune reactions, compliance with adult vaccination programs, nutritional profiles, presence of metabolic syndrome, fertility status, pregnancy outcomes, and vitamin D levels will be recorded in the outpatient clinic. Rheumatoid Arthritis Impact of Disease, Psoriatic Arthritis Impact of Disease (RAID and PSAID indexes), Work Productivity and Activity Impairment Questionnaire (WPAI), drug compliance, central sensitization and fall risk will be evaluated with verbal evaluation forms performed at policlinic controls in patients with spondyloarthritis and rheumatoid arthritis. It is planned to conduct scientific analyzes and publish on various subjects from the recorded information on this registration system. Patients using biological and targeted synthetic DMARD treatments are closely monitored and evaluated in many ways due to the risk profiles and various characteristics of the drugs. With this registry system, it is aimed to evaluate the real-life data of the participants using these drugs. Real-life data are very valuable in monitoring the disease and the drugs. The study is observational and there is no expected risk since no intervention is planned.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.
    Bodur H, Yurdakul FG, Ataman S, Cay HF, et al · · 2022 · cited 3× · PMID 35353263 · DOI 10.1007/s10067-022-06145-8

Verify or expand the search:

Other trials of There is no intervention in the study

Trials testing the same drug.

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

Other Turkish League Against Rheumatism trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04139954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing